mortality:amodellingstudy.Lancet391,1285–1300(2018).
2. WorldHealthOrganization.Fact-sheet.Influenza(Seasonal).Availableathttps://
www.who.int/en/news-room/fact-sheets/detail/influenza-(seasonal).Accessed12
March2021.(2018).
3. Lafond,K.E.etal.Globalburdenofinfluenza-associatedlowerrespiratorytract
infections and hospitalizations among adults: a systematic review and meta-
analysis.PLoSMed.18,e1003550(2021).
4. US Centers for Disease Control and Prevention (CDC). Weekly U.S. Influenza
Surveillance Report. https://www.cdc.gov/flu/weekly/index.htm. Accessed 16
March2021.
5. Sellers,S.A.,Hagan,R.S.,Hayden,F.G.&Fischer,W.A.IIThehiddenburdenof
influenza:areviewoftheextra-pulmonarycomplicationsofinfluenzainfection.
InfluenzaOtherRespir.Viruses11,372–393(2017).
6. deFranciscoShapovalova,N.,Donadel,M.,Jit,M.&Hutubessy,R.Asystematic
review of the social and economic burden of influenza in low- and middle-
incomecountries.Vaccine33,6537–6544(2015).
7. Szucs,T.Thesocio-economicburdenofinfluenza.J.Antimicrob.Chemother.44
SupplB,11–15(1999).
8. Krammer,F.etal.Influenza.Nat.Rev.Dis.Prim.4,3(2018).
9. Paules,C.&Subbarao,K.Influenza.Lancet390,697–708(2017).
10. Hobson, D., Curry, R. L., Beare, A. S. & Ward-Gardner, A. The role of serum
haemagglutination-inhibitingantibodyinprotectionagainstchallengeinfection
withinfluenzaA2andBviruses.Epidemiol.Infect.70,767–777(1972).
11. Ohmit,S.E.etal.Influenzahemagglutination-inhibitionantibodytiterasacor-
relateofvaccine-inducedprotection.J.Infect.Dis.204,1879–1885(2011).
12. Dunkle,L.M.etal.Efficacyofrecombinantinfluenzavaccineinadults50yearsof
ageorolder.N.Engl.J.Med.376,2427–2436(2017).
13. Wohlbold,T.J.&Krammer,F.Intheshadowofhemagglutinin:agrowinginterest
in influenza viral neuraminidase and its role as a vaccine antigen. Viruses 6,
2465–2494(2014).
14. Giurgea, L. T., Morens, D. M., Taubenberger, J. K. & Memoli, M. J. Influenza
neuraminidase:aneglectedproteinanditspotentialforabetterinfluenzavac-
cine.Vaccines8,409(2020).
15. WorldHealthOrganization.GlobalInfluenzaSurveillanceandResponseSystem
(GISRS). Available at https://www.who.int/influenza/gisrs_laboratory/en/. Acces-
sed17February2021.(2021).
16. Camilloni,B.,Neri,M.,Lepri,E.&Iorio,A.M.Cross-reactiveantibodiesinmiddle-
agedandelderlyvolunteersafterMF59-adjuvantedsubunittrivalentinfluenza
vaccineagainstBvirusesoftheB/VictoriaorB/Yamagatalineages.Vaccine27,
4099–4103(2009).
17. Tricco,A.C.etal.Comparinginfluenzavaccineefficacyagainstmismatchedand